Stan Chetcuti
Overview
Explore the profile of Stan Chetcuti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaneko T, Newell P, Nisivaco S, Yoo S, Hirji S, Hou H, et al.
J Thorac Cardiovasc Surg
. 2022 May;
167(1):143-154.e6.
PMID: 35570022
Objective: The use of transcatheter edge-to-edge repair (TEER) is growing substantially, and reintervention after TEER by way of repeat TEER or mitral valve surgery (MVS) is increasing as a result....
2.
Gleason T, Reardon M, Popma J, Deeb G, Yakubov S, Lee J, et al.
J Am Coll Cardiol
. 2018 Sep;
72(22):2687-2696.
PMID: 30249462
Background: The CoreValve U.S. Pivotal High Risk Trial was the first randomized trial to show superior 1-year mortality of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement...
3.
Gaudiani V, Deeb G, Popma J, Adams D, Gleason T, Conte J, et al.
J Thorac Cardiovasc Surg
. 2017 Mar;
153(6):1293-1301.e1.
PMID: 28249691
Objective: Explore causes and timing of death from the CoreValve US Pivotal High-Risk Trial. Methods: An independent clinical events committee adjudicated causes of death, followed by post hoc hierarchical classification....
4.
Popma J, Reardon M, Khabbaz K, Harrison J, Hughes G, Kodali S, et al.
JACC Cardiovasc Interv
. 2017 Feb;
10(3):268-275.
PMID: 28183466
Objectives: This study sought to evaluate this transcatheter aortic valve (TAV) bioprosthesis in patients who are poorly suitable for surgical aortic valve (AV) replacement. Background: A novel self-expandable TAV bioprosthesis...
5.
Reardon M, Kleiman N, Adams D, Yakubov S, Coselli J, Deeb G, et al.
JAMA Cardiol
. 2016 Aug;
1(8):945-949.
PMID: 27541162
Importance: Transcatheter aortic valve replacement (TAVR) is now a well-accepted alternative to surgical AVR (SAVR) for patients with symptomatic aortic stenosis at increased operative risk. There is interest in whether...
6.
Deeb G, Reardon M, Chetcuti S, Patel H, Grossman P, Yakubov S, et al.
J Am Coll Cardiol
. 2016 Apr;
67(22):2565-74.
PMID: 27050187
Background: In patients with severe aortic stenosis at increased risk for surgery, self-expanding transcatheter aortic valve replacement (TAVR) is associated with improved 2-year survival compared with surgery. Objectives: This study...
7.
Reardon M, Adams D, Kleiman N, Yakubov S, Coselli J, Deeb G, et al.
J Am Coll Cardiol
. 2015 Jun;
66(2):113-21.
PMID: 26055947
Background: The U.S. pivotal trial for the self-expanding valve found that among patients with severe aortic stenosis at increased risk for surgery, the 1-year survival rate was 4.9 percentage points...
8.
Reardon M, Adams D, Coselli J, Deeb G, Kleiman N, Chetcuti S, et al.
J Thorac Cardiovasc Surg
. 2014 Aug;
148(6):2869-76.e1-7.
PMID: 25152474
Objectives: The CoreValve Extreme Risk US Pivotal Trial enrolled patients with symptomatic severe aortic stenosis deemed unsuitable for surgical aortic valve replacement. Implants were attempted using transfemoral access (n =...
9.
Adams D, Popma J, Reardon M, Yakubov S, Coselli J, Deeb G, et al.
N Engl J Med
. 2014 Apr;
370(19):1790-8.
PMID: 24678937
Background: We compared transcatheter aortic-valve replacement (TAVR), using a self-expanding transcatheter aortic-valve bioprosthesis, with surgical aortic-valve replacement in patients with severe aortic stenosis and an increased risk of death during...